CE
Cell Bio Human Tech Co., Ltd
318160 | KO
Overview
Corporate Details
- ISIN(s):
- KR7318160009
- LEI:
- Country:
- South Korea
- Address:
- 경기도 안양시 동안구 시민대로 401 대륭테크노타운15차 제2001호,제2101호, 안양시
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 31.8 KB | ||
| 2025-09-19 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 53.0 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 28.2 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 28.2 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
신탁계약해지결과보고서
|
Korean | 20.6 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
신탁계약해지결과보고서
|
Korean | 22.3 KB | ||
| 2025-08-28 00:00 |
Transaction in Own Shares
[기재정정]주요사항보고서(자기주식취득신탁계약해지결정)
|
Korean | 31.1 KB | ||
| 2025-08-28 00:00 |
Interim / Quarterly Report
[기재정정]반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-08-18 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-06-02 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2025-05-27 00:00 |
Major Shareholding Notification
신탁계약에의한취득상황보고서
|
Korean | 52.6 KB | ||
| 2025-05-27 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-05-14 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-04-02 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.4 KB |
Automate Your Workflow. Get a real-time feed of all Cell Bio Human Tech Co., Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Cell Bio Human Tech Co., Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cell Bio Human Tech Co., Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing Alpha DaRT, a precision alpha-radiation therapy designed to destroy solid tumors.
United States of America
DRTS
United States of America
DRTS
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea
196170
South Korea
196170
Develops small-molecule drug therapies for Alzheimer's, pain, and cognitive dysfunction.
Sweden
ALZCUR
Sweden
ALZCUR
Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.
United States of America
ANAB
United States of America
ANAB
Develops anti-angiogenic therapeutics and foods for angiogenesis-related diseases.
South Korea
251280
South Korea
251280
Clinical-stage biotech developing CAR-T immunotherapies and vaccines to fight cancer.
United States of America
ANIX
United States of America
ANIX
Developing oral therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
United States of America
ANVS
United States of America
ANVS
United States of America
APDN
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
United States of America
APRE
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
South Korea
397030